StockData
Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc. (HALO) income statement

HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3034% above fair value
$91.35−1.69 (-1.82%)

Close on Nov 20, 2026Market cap $10.37BP/E 26.9Yield –

Halozyme Therapeutics, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
82.4%
Operating margin
35.9%
Net margin
24.9%
Return on equity, FY2025
153.6%

Financial strength

Current ratio
2.71
Debt to equity
14.95
Debt to assets
83.3%
Cash to current liabilities
47.4%

Valuation

P/E ratio
26.9
Price to sales
6.23
Price to book
72.23
Dividend yield
–

See a number that looks wrong?